Biogen (BIIB) Presents Updates Across SMA Research Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Biogen (BIIB) Presents Updates Across SMA Research Program

Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

March 14, 2022 7:30 AM EDT

First patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi® (risdiplam)
Baseline characteristics indicate all nine infants and toddlers enrolled in RESPOND had suboptimal clinical status in 2 areas after receiving Zolgensma® (onasemnogene abeparvovec); there were no new safety findings with subsequent SPINRAZA® (nusinersen) treatmentNew NURTURE results continue to show the potential long-term benefit of early treatment before SMA symptom onset, with 92 percent of participants now able to walk alone, most in age-appropriate timelines
... More